The approach of molecular medicine to the treatment of Gaucher disease

Abstract

Gaucher disease presents a metabolic rare disease with the autosomal recessive transmission. The cause of this monogenic disease is the mutation of the gene GBA. As a consequence of this mutation, a deficiency of synthesis of the enzyme β- gucocerebrosidase occurs. As a result, glucocerebrosides accumulate throughout the body, especially in the bone marrow, spleen and liver. Three different forms of Gaucher disease have been determined, distinguished by the absence or presence and extent of neurological complications. Currently, five therapies for the treatment of Gaucher disease are described. This review study provides the most recent information on the therapies approved for the treatment of the disease.